Mentions
Extended reach
Total likes
Video views
AI synopsis
Several posts reference the trial's significance by sharing publication links and discussing potential treatment implications, using tone and words such as 'evidence' and 'new approach.' Others mention limitations and call for further research, indicating a nuanced view with recognition of both the study's potential and its constraints.
Most discussions acknowledge the study's importance but also highlight its limitations, such as retrospective data and limited patient numbers, indicating cautious acknowledgment rather than strong consensus.
Posts demonstrate moderate curiosity, with many referencing specific details of the trial and its implications, showing an interest in the new evidence regarding docetaxel's use.
Some discussions analyze the methodology and clinical relevance, reflecting a deeper level of engagement, though many mainly share summaries or links to the publication.
While the study appears to be recognized as an important step, the emphasis on limitations and preliminary nature suggests perceived moderate to substantial impact, but not a definitive breakthrough.
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/0IuEUvVUQo
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | More nice work from Tata Memorial @JCO_ASCO https://t.co/kr3iIVkHMQ
✅ Check out what’s popular this week in #JCO: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With #HeadAndNeckCancer, Unsuitable for Cisplatin-Based #Chemoradiation ➡️ https://t.co/GlvU06gNnO #radonc #medonc #hncsm https://t.co/cl48Rm4bz1
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/WRekT9ruJF
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/p9FIWqF3YQ
Now, we have evidence for Docetaxel as concurrent chemo Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | Journal of Clinical Oncology https://t.co/9tE6pewd1P
For more information visit httpsascopubsorgdoiabs101200JCO2200980. This video reviews research on using Docetaxel as a radiosensitizer in treating head and neck cancer, especially for patients unsuitable for…
Cisplatin is the mainstay for chemoradiotherapy in Head and Neck cancers. This video explores the potential of docetaxel as an alternative for patients unable to tolerate cisplatin, highlighting recent trial findings…
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | Journal of Clinical Oncology https://t.co/gzeiryqJGT
(15/n) Some limitations are: ▶️ retrospective data and therefore no exact information regarding prevalence of cisplatin ineligibility and CGA ▶️ docetaxel (despite very good data: https://t.co/3CAc68LajF) used in few patients ▶️high-dose cisplatin also used in only few patients
Conversamos com ele sobre o artigo “Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation”, publicado no Journal of Clinical Oncology (JCO), em janeiro de 2023.
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. https://t.co/q0iJbpKrh8
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/iIbXLAOv29 #Oncology
RT @JCO_ASCO: ✅ Check out what’s popular this week in #JCO: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitize…
RT @JCO_ASCO: ✅ Check out what’s popular this week in #JCO: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitize…
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/p9FIWqF3YQ
RT @JCO_ASCO: ✅ Check out what’s popular this week in #JCO: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitize…
✅ Check out what’s popular this week in #JCO: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With #HeadAndNeckCancer, Unsuitable for Cisplatin-Based #Chemoradiation ➡️ https://t.co/GlvU06gNnO #radonc #medonc #hncsm https://t.co/cl48Rm4bz1
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | Journal of Clinical Oncology https://t.co/cWADRpKGrw
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/WRekT9ruJF
RT @rbryanbell: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsu…
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
RT @vmathrudev: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsu…
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/2vs7SbkEpS
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
RT @rbryanbell: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsu…
RT @rbryanbell: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsu…
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | More nice work from Tata Memorial @JCO_ASCO https://t.co/kr3iIVkHMQ
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
RT @Nandinimenon18: Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer,…
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/COknsqE2no
Now, we have evidence for Docetaxel as concurrent chemo Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | Journal of Clinical Oncology https://t.co/9tE6pewd1P
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/0IuEUvVUQo
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/OZmk0Gz2x8
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | Journal of Clinical Oncology https://t.co/M1lM35duEN
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation https://t.co/wVGSWitEWE